Description

Xarelto (rivaroxaban) coated tablets 20 mg. №100

Ingredients

Active ingredient: Rivaroxaban.
Other ingredients: Croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.

Dosage

Recommended dosage: The usual dose is 20 mg once daily with the evening meal. Consult a healthcare professional for personalized dosing instructions.

Indications

Xarelto 20 mg tablets are indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Contraindications

Do not use Xarelto if: you have active pathological bleeding, severe liver disease, or if you are pregnant. Consult your doctor for a full list of contraindications.

Directions

Take Xarelto tablets exactly as prescribed by your healthcare provider. Swallow the tablet whole with water. Do not crush, chew, or break the tablet.

Scientific Evidence

Rivaroxaban, the active ingredient in Xarelto, has been extensively studied in clinical trials. Research has shown that rivaroxaban is non-inferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. Additionally, rivaroxaban has a rapid onset of action and does not require routine monitoring like warfarin.

Additional Information

It is important to follow your healthcare provider’s instructions carefully while taking Xarelto. Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements, to prevent potential drug interactions. If you experience any unusual bleeding or bruising while taking Xarelto, contact your healthcare provider immediately.

Pharmacological Effects: Xarelto works by inhibiting Factor Xa, a key component in the coagulation cascade. By blocking Factor Xa, Xarelto prevents the formation of thrombin, thereby reducing the risk of blood clot formation.

Clinical Trials: Clinical trials have demonstrated the efficacy and safety of Xarelto in various patient populations. The ROCKET AF trial compared rivaroxaban with warfarin in patients with atrial fibrillation and showed that rivaroxaban was as effective as warfarin in preventing stroke and systemic embolism, with a lower risk of intracranial hemorrhage.